Safety, Tolerability and Preliminary Efficacy of NEUK203-13 in Refractory Neuroendocrine Tumor Patients
Safety, Tolerability and Preliminary Efficacy of NEUK203-13 in Refractory Neuroendocrine Tumor Patients (NCT07366658)
OrganizationBiotech
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Organization linked by public source evidence.
Public IDs
No public external ID is attached.
Related people
No reviewed person affiliation is attached.
Outputs
No reviewed output is linked through affiliated people.
Topics
Relationship evidence
Timeline
No dated relationship evidence is attached.